Conference on Diabetes and Diabetic Retinopathy

Venue: BSG Conference House

Location: London, London, United Kingdom

Event Date/Time: Jan 21, 2010 End Date/Time: Jan 22, 2010
Report as Spam



Attenuating the progression of hyperglycaemia, dyslipidaemia and angiopathy
21st - 22nd January 2010, BSG House, London, UK

Background Info
Key Speakers
• Peter Adamson, Head of Research, Ophthiris, GlaxoSmithKline
• Riccardo Perfetti, Senior Medical Director, Diabetes & Metabolism Global Franchise, Sanofi-Aventis
• Richard Carr, Senior Director, Merck Sharp & Dohme
• Rafaella Balena, Vice Director of Clinical Science & Leader of Medical Science, F. Hoffmann-La Roche
• Michael Trautmann, Medical Fellow, Global Exanatide Team, Lilly
• Matthew Sheetz, Medical Fellow, Lilly
• Piet Pijper, Global Development Project Leader, Astellas
• Paul Ashton, President & Chief Executive Officer, pSivida
• Stanley Wiegand, Vice President, Ophthalmology and Cardiovascular Research, Regeneron Pharmaceuticals
• Patricia Cole, Executive Director and Head of Imagepace, Medpace
• Didier Pruneau, Head of Scientific Operations, Fovea Pharmaceuticals
• Edward Feener, Associate Professor of Medicine, Harvard Medical School
• Victor Chong, Consultant Ophthalmologist, University of Oxford
• Adnan Tufail, Consultant Ophthalmologist, Moorfields Eye Hospital
• Arnd Gandorfer, Professor of Ophthalmology and Deputy Chairman, University Eye Hospital Munich
• Pascale Massin, Principal Investigator, Hôpital Lariboisière
• Dirk Kars, Partner, Simon-Kucher & Partners
Managing toxic glucose and fat concentrations in the vasculature remain significant challenges for diabetics. As the numbers of patients affected by the disease climbs, so secondary vascular and ophthalmic complications affecting patients continue to grow. With up to 50 million people currently affected by diabetic eye diseases and 100 million forecast by 20251, more effective therapeutics are desperately needed.

Set to double from $32bn to $64bn over the next 15 years2, the global diabetes market is set for stellar growth as changing demographics and new therapies begin entering the clinic.

Focussing on efforts to reduce hyperglycaemia, dyslipidaemia and angiopathy, Diabetes and Diabetic Retinopathy conference concentrates on the latest developments in this area. We bring you distilled insights from outstanding speakers in key areas including:

• Full market analysis, including medical needs and commercial opportunities
• Novel GLP1 receptor agonists, and SLGT2 and DPP-4 inhibitors
• The use of biomarkers and imaging for the development of novel therapies for diabetes
• New therapeutic targets to reduce inflammation and cardiovascular disease in diabetes
• Overcoming microangiopathy and capillary occlusion
• Epidemiology and pharmacotherapies for diabetic eye diseases
• The effects of ACE, RAS and PKC inhibitors on the progression of diabetic retinopathies
• Clinical results from the EUCLID, DIRECT and RASS studies
• New data on intravitreal VEGF and PLGF signalling inhibitors
• Corticosteroid implants to reduce intra-ocular vascular permeability and oedema
• Blockade of the kallikrein-kinin system to treat diabetic retinopathy

Who should attend?

Presidents, Chief Executives, Chief Scientific Officers, Chief Operating Officers, Senior Vice Presidents, Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Principal Investigators, Managers, Project/Team Leaders in:
• Diabetes & Obesity, Clinical R&D
• Retinal Diseases
• Ophthalmology, Visual Science and Vision Research
• Endocrinology and Metabolic Diseases
• Cardiovascular and Gastrointestinal Diseases
• Anti-Diabetic Agents & Advanced Diabetes Systems
• Biomarkers
• Imaging and Translational Medicine
• Drug Development
• Monoclonal Antibodies
• Molecular Neuroscience
• New Products Global Marketing
• Business Development, Licensing & Partnership
• Venture Capital

Day 1
Day One, Thursday 21st January 2010 09:30 Registration and refreshments

10:00 Opening address from the Chair

Johannes Zanzinger
Head, Global Licensing Cardio-Metabolic Diseases

10:10 Market access challenges and opportunities for innovative diabetes drugs
• What payers expect in diabetes
• The market access situation of innovative diabetes drugs
• Trends in innovative market access approaches: what can manufacturers of diabetes drugs learn from other indications?
• Implications for the industry

Dirk Kars
Simon-Kucher & Partners

10:50 Incretin-based therapies for type 2 diabetes mellitus
• Differences between oral agents (DPP IV inhibitors) and injectable GLP-1 receptor agonists
• Optimising the stimulation of GLP-1 receptors and potential limitations: conclusions from FDA advisory hearings
• Clinical efficacy of GLP-1 receptor agonists

Michael Trautmann
Medical Fellow, Global Exanatide Team

11:30 Morning refreshments

11:50 Ave010: a novel GLP receptor agonist
• Incretin action and postprandial glucose control
• Daily treatment regimens to facilitate compliance
• Weight control and the management of hyperglycaemia

Riccardo Perfetti
Senior Medical Director, Diabetes & Metabolism Global Franchise

12:30 New developments in a glucagon-like peptide 1 candidate
• Effects on circulating glucose and lipid levels
• Effects on glycosylated HbA concentration
• Prospects for phase III studies

Rafaella Balena
Vice Director of Clinical Science & Leader of Medical Science
F. Hoffmann-La Roche

13:10 Networking lunch

14:10 SGLT2 inhibitors for the treatment of diabetes
• The mechanism: inhibition of renal glucose re-uptake
• The concept: glycaemic control through urinary glucose excretion
• The therapeutic potential in the treatment of diabetes: benefits and risks

Piet Pijper
Global Development Project Leader

14:50 Imaging biomarkers in drug development for assessment of diabetes and diabetic complications
• Beta cell detection/stabilisation
• Obesity
• Peripheral neuropathy/pain
• Cardiovascular disease
• Diabetic retinopathy

Patricia Cole
Executive Director and Head
Imagepace, the Imaging Core Lab of Medpace

15:30 Afternoon refreshments

15:50 Therapeutic targets to reduce cardiovascular disease in type 2 diabetes
• Links between diabetes and CVD
• Novel diabetes drugs and CVD
• Future directions

Richard Carr
Senior Director
Merck Sharp & Dohme

16:30 Inflammatory processes in retinal microvascular disease
• Intracellular programs of retinal inflammation in diabetes
• Insights into diabetic retinopathy from vitreous proteomics
• Targeting inflammatory pathways for diabetic retinopathy

Edward P. Feener
Associate Professor of Medicine,
Harvard Medical School and Investigator,
Joslin Diabetes Center

17:10 Microvascular complications to diabetes, with focus on retinopathy. What is the evidence for treatment with RAS inhibitors?
• Retinal lesions as markers of macro and microvascular complications in diabetes
• The role of blood pressure on retinopathy
• Evidence of the effect of RAS inhibitors on the incidence and progression of retinopathy

17:50 Closing remarks from the chair

18:00 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting

Day 2
Day Two, Friday 22nd January 2010

09:30 Registration and refreshments

10:00 Opening address from the Chair

Peter Adamson
Head of Research, Ophthiris

10:10 Pharmacotherapies for diabetic retinopathy
• Overview of DR and DME
• Trends in diabetic eye disease rates
• Current treatments and their shortcomings

Adnan Tufail
Consultant Ophthalmologist
Moorfields Eye Hospital

10:50 Optical coherence tomography and other methods to aid pre-clinical and clinical research for diabetic retinopathies

Pascale Massin
Principal Investigator
Hôpital Lariboisière

11:30 Morning refreshments

11:50 Ocular drug delivery in diabetic retinopathy
• Barriers to clinically effective therapies
• Emerging drug delivery technologies
• Clinical data

Paul Ashton
President & Chief Executive Officer

12:30 Development of the VEGF Trap-Eye for treatment of ocular vascular diseases
• Rationale for the molecular design of VEGF Trap-Eye
• Properties and preclinical evaluation of VEGF Trap-Eye
• Clinical experience with VEGF Trap-Eye

Stanley Wiegand
Vice President, Ophthalmology and Cardiovascular Research
Regeneron Pharmaceuticals

13:10 Networking lunch

14:30 Anti-VEGF agents for diabetic eye complications
• Pathogenesis of diabetic retinopathy
• Anti-VEGF for proliferative diabetic retinopathy
• Anti-VEGF for diabetic macular oedema

Victor Chong
Consultant Ophthalmologist
University of Oxford

15:10 Microplasmin-assisted vitrectomy
• The vitreous as a target for pharmacology
• Pharmacology-assisted vitreoretinal surgery
• Preclinical and clinical assessment of microplasmin

Arnd Gandorfer
Professor of Ophthalmology and Deputy Chairman
University Eye Hospital Munich

15:45 Afternoon refreshments

16:10 The PKC beta inhibitor, ruboxistaurin, for diabetic retinopathy: recent results and status update
• Ruboxistaurin development history
• Recent results in diabetic retinopathy
• Ongoing studies

Matthew Sheetz
Medical Fellow

16:50 Blockade of the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy
• The kallikrein-kinin system (KKS)
• Role of the KKS in diabetic retinal inflammation
• Development of a kinin B1 receptor antagonist administered topically

Didier Pruneau
Head of Scientific Operations
Fovea Pharmaceuticals

17:30 Chair’s closing remarks

17:40 End of conference


BSG Conference House
United Kingdom